Company Overview
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Why Investors Should Care
Generates a return on equity of 25.7%, reflecting efficient use of shareholder capital.
Net profit has compounded at 22.1% per year over the last five years.
Trades at a P/E of 18.0, below the sector median of 25.2.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $568.09M (-0.9% YoY); net profit $22.73M.
- Trailing 12 Months Year-on-year growth — revenue +3.8%, earnings +327.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.9%, profit CAGR 22.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.92% |
| 1 Year: | 3.80% |
Compounded Profit Growth
| 5 Years: | 22.13% |
| 1 Year: | 327.30% |
Stock Price Performance
| 1 Year: | +86.85% |
| 6 Months: | +67.30% |
| 3 Months: | +55.64% |
| 1 Month: | +0.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.53 · Neutral
P/E of 18.04 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 25.7%.
- Profit CAGR of 22.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BVS Bioventus Inc. R2KR3KPHARMA | 14.07 | 18.04 | $961.05M | 0.00% | 10.32% | 25.68% | 8.92% | 22.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78.64M | 58.02M | 85.91M | 81.78M | 109.82M | 108.89M | 117.29M | 140.33M | 128.66M | 119.06M | 137.07M | 120.79M | 129.46M | 151.22M | 138.96M | 123.88M | 147.66M | 138.65M | 132.09M | 153.21M |
| Gross Profit | 57.24M | 40.35M | 62.46M | 59.56M | 76.31M | 79.07M | 75.70M | 96.65M | 84.53M | 73.92M | 89.12M | 78.85M | 88.38M | 103.64M | 93.55M | 83.06M | 102.09M | 94.23M | 90.77M | 105.67M |
| Operating Income | 12.99M | -4.59M | 6.93M | 22.00M | -5.74M | -1.05M | -21.45M | -3.31M | -126.84M | -92.06M | 6.75M | 2.42M | 4.93M | -31.47M | 3.65M | 4.87M | 18.37M | 11.25M | 8.42M | 19.13M |
| Net Income | 10.94M | -5.77M | 8.46M | 24.94M | -4.13M | -1.07M | -11.28M | -7.25M | -108.25M | -139.15M | -3.68M | -7.30M | -4.89M | -25.68M | -5.17M | -2.64M | 7.46M | 3.15M | 3.11M | 33.44M |
| Diluted EPS | - | - | - | -0.02 | -0.10 | -0.03 | -0.19 | -0.11 | -1.76 | -2.24 | -0.06 | -0.12 | -0.08 | -0.40 | -0.08 | -0.04 | 0.11 | 0.05 | 0.04 | 0.47 |
| R&D Expense | 2.15M | 2.60M | 3.57M | 947.00K | 4.84M | 6.15M | 6.93M | 6.37M | 4.61M | 3.77M | 3.40M | 3.02M | 2.63M | 4.21M | 3.84M | 3.01M | 3.17M | 2.92M | 2.47M | 3.17M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 340.14M | 321.16M | 430.90M | 512.12M | 512.35M | 573.28M | 568.09M |
| Gross Profit | 249.21M | 233.52M | 302.71M | 331.08M | 328.19M | 388.23M | 388.16M |
| Operating Income | 31.19M | 21.24M | 12.06M | -167.23M | -81.72M | -15.20M | 53.98M |
| Net Income | 6.85M | 16.41M | 19.38M | -158.70M | -156.23M | -36.12M | 22.73M |
| Diluted EPS | - | - | -0.15 | -2.59 | -2.49 | -0.56 | 0.33 |
| R&D Expense | 11.05M | 11.20M | 19.04M | 23.85M | 13.45M | 13.95M | 12.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 494.47M | 1.23B | 1.37B | 810.91M | 727.96M | 683.56M |
| Total Equity | - | 458.92M | 325.24M | 173.59M | 147.94M | 184.10M |
| Cash & Equivalents | 86.84M | 43.93M | 30.19M | 36.96M | 41.58M | 51.24M |
| Long Term Debt | 173.38M | 339.64M | 385.01M | 367.00M | 308.29M | 278.95M |
| Total Liabilities | 350.31M | 618.21M | 960.43M | 589.79M | 542.35M | 455.11M |
| Current Liabilities | 122.59M | 180.86M | 304.02M | 175.50M | 210.40M | 160.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 40.71M | 71.80M | 22.99M | -13.54M | 15.34M | 38.80M | 74.67M |
| Investing Cash Flow | -7.91M | -20.50M | -283.76M | -116.44M | 15.81M | 22.96M | -3.25M |
| Financing Cash Flow | -10.95M | -29.57M | 273.37M | 62.08M | -26.65M | -54.58M | -62.14M |
| Capital Expenditure | -2.34M | -16.58M | -13.52M | -1.48M | -7.36M | -1.01M | -2.56M |
| Free Cash Flow | 38.37M | 55.22M | 9.47M | -15.02M | 7.98M | 37.79M | 72.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.3% | 72.7% | 70.3% | 64.6% | 64.1% | 67.7% | 68.3% |
| Operating Margin % | 9.2% | 6.6% | 2.8% | -32.7% | -16.0% | -2.7% | 9.5% |
| Net Margin % | 2.0% | 5.1% | 4.5% | -31.0% | -30.5% | -6.3% | 4.0% |
| ROE % | - | - | 4.2% | -48.8% | -90.0% | -24.4% | 12.3% |
| ROCE % | - | 5.7% | 1.2% | -15.6% | -12.9% | -2.9% | 10.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Essex Woodlands Management Inc. | 19.06% | 13.02M | $180.22M |
| 2 | Juniper Investment Company, LLC | 10.16% | 6.94M | $96.04M |
| 3 | Nantahala Capital Management, LLC | 8.78% | 6.00M | $83.04M |
| 4 | Blackrock Inc. | 5.03% | 3.44M | $47.55M |
| 5 | Royce & Associates LP | 2.68% | 1.83M | $25.37M |
| 6 | Vanguard Capital Management LLC | 2.56% | 1.75M | $24.24M |
| 7 | Geode Capital Management, LLC | 2.00% | 1.37M | $18.90M |
| 8 | American Century Companies Inc | 1.98% | 1.35M | $18.73M |
| 9 | Dimensional Fund Advisors LP | 1.65% | 1.13M | $15.62M |
| 10 | State Street Corporation | 1.62% | 1.10M | $15.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BVS
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNdkwwU1JqbHdMcnRJTjl4RlVhRXFBZk04TGpLbFF6WVFIZjN6RTVtdnJWTUNFVHRWWWxaeW1VNVJMXzlIdkFXQ3pxVWtaUFhZeWpUS2ZkMF9nMjBhRVBfOXpENElNQ2p1ZjRvRUlKNkFINExhSGl6SkdOMVAwMVp4ODF0aEplNkNNVWNUS2…
Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOTnZoNHRZYVZmMUNMTlc4dVdzS0lGd2lFUkxFZGU4QWdBSGRXODRya2VVTTJkTWlwRnNWbEk5cHB5RWFJN1dWMS1DT0hHbXlocmJJS0d4aWxfQlNPZ3pqTmF1YW0tNVltQ0FEZ3NNal9YZWpmZEpQLWpSeVJMOFVQS3diWV80ekMwN3dNen…
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNVl9zRTZCOTRFcG42bFJEdEtrVWNyLThZMm5EbVdHRzc3SXVoSnB4WEFYLXhHS2pHMDJWSGJpanY0YlVUT2xJQXp0Z3hlR0phS29KaDRsVk5xbVM2VU1QN1NMRGhSaV9IbE1TU3BVcXllT3lyMVJEMFIyN29GUDRtNDFFLUU4eHN1ZjlqdT…
Bioventus Stock (BVS) Opinions on Strategic Review Announcement - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNTmxRcVduZ0VZSk42cmJiMFBrbTM4MzYtQ0tjZXl5dTYtNG1SMFJGMHNGNUxDcmEyN193elNyLUxhSVpRRWNMRDg0Zml0QngtbnN5VF9NUGZPTWZvbmhmcUM5ZTJfWDlPQUV5Y3gzYnBJZGFjR3RQUWwtTzAzNWN6TnotV0JKUWFWLTF2bH…
Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPTjQ5U05PZ0g2MmF0WXlReGUxYjZuZlFqOXExVG96Vk9UbWxKeGUwNUdjTlY0UE81Q1V5VnN3WWUwUUMwRFBKdEc0RldFalhGelhDRVJ0VUNKQTVHbWxESzRuSzhCVUlIR3BZWGR6ZU9XQnFrQWxRU1dBWTZRY2t4MVRqcjVPekNuTGdRVW…
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxObWMzc1lKWkNMemFPTkVQeXBzV2RYUkxWZzZuVEVOUXhXSjFrcTB3UU11NTV4S2F5RkNBaUZEU1VGUUpQczZKYUxUMWZMeXd3akJBeUc1RFpRNXBuOXVQZVJSWnNBRk03cDJWN3VxV2xUbTA5b2x3NE9UcVV1bU41Q1V5eFRWUjdlRkNrMj…
BVS — Frequently Asked Questions
What is the current share price of Bioventus Inc. (BVS)?
As of 2026-09-07 16:24 PDT, Bioventus Inc. (BVS) trades at $14.07 on NasdaqGS. Its 52-week range is $6.51 to $15.26.
What is the market capitalisation of BVS?
Bioventus Inc. (BVS) has a market capitalisation of $961.05M on NasdaqGS.
What is the P/E ratio of BVS?
BVS trades at a trailing price-to-earnings (P/E) ratio of 18.04. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.15.
What is the return on equity (ROE) of BVS?
BVS has a return on equity (ROE) of 25.68%. Its return on capital employed (ROCE) is 10.32%.
Is BVS a good stock to buy?
This page provides a data-driven analysis of Bioventus Inc. (BVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.